Abstract

The two techniques of flow cytometry analysis (FCM) and immunohistochemical localisation of bromodeoxyuridine (BrdUrd) incorporation after in vivo administration, were combined to study proliferation in squamous cell carcinoma of the head and neck region. Care was taken in this study to ensure that similar material was processed using both techniques such that comparisons could be made. FCM underestimated the labelling index (LI) in tumours classified as diploid compared to the histological evaluation of the tumour cells within those tumours (4.6% vs 17.1%). However, in aneuploid tumours, the FCM LI (10.7%) was similar to that obtained from histology (13.5%). Indeed, proliferation assessed by the combination of histology LI and FCM duration of S-phase (Ts) indicated that diploid tumours had a shorter median potential doubling time (Tpot) of 2.1 days compared to aneuploid (2.8 days). Despite the heterogeneity of proliferation evident histologically within the specimens, there was not a wide variation in the results of FCM analysis when multiple samples from resections were studied. Using FCM data alone, 46% of the tumours showed a Tpot of less than 5 days. When the Ts from the FCM data was combined with the average histological LI, 84% were less than 5 days and with the maximum LI, 99% were within this time interval. Compared with previous estimates, the proportion of tumours possessing proliferative characteristics which may indicate the need for acceleration of treatment seems to be much larger.

Highlights

  • Using bromodeoxyuridine (BrdUrd) and a technique developed by Begg et al (1985), it is possible to determine tumour cell kinetics in human tumours safely and speedily

  • This paper reports the finding by flow cytometry and by histological study after BrdUrd administration, and discusses the implications of the results for clinical radiotherapy

  • The corrected average labelling index (LI) was 17.4%. This was in contrast to the flow cytometry analysis (FCM) data, in which the LI was only 3.9% (Figure 3a)

Read more

Summary

Introduction

Using bromodeoxyuridine (BrdUrd) and a technique developed by Begg et al (1985), it is possible to determine tumour cell kinetics in human tumours safely and speedily. Since 1985, we have been giving patients an intravenous injection of BrdUrd 4 to 6 h prior to biopsy or surgical removal and the series extends to over 500 patients

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.